the first dose was administered on August 12th 2024 and the second dose on January 2nd 2025.; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 43-year-old male patient who received HAB (Twinrix) (batch number D4774, expiry date 12-SEP-2026) for prophylaxis. Previously administered products included Twinrix (received 1st dose on 12-AUG-2024). On 02-JAN-2025, the patient received the 2nd dose of Twinrix. On 02-JAN-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: the first dose was administered on August 12th 2024 and the second dose on January 2nd 2025.). The outcome of the drug dose administration interval too long was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 02-JAN-2025 The pharmacist called to verify when the 3rd dose of Twinrix should be administered if the first dose was administered on 12th August 2024 and the second dose on 2nd January 2025. the patient received the 2nd dose of Twinrix later than the recommended interval, which led to lengthening of vaccine schedule. The vaccine administration facility was the same as primary reporter.; Sender’s Comments: US-GSK-US2025000316:Same reporter/ Different patient (Wife case)